In the biotech market, Waters Corporation (WAT) continues to attract attention as an appealing choice for investment. It has seen a surge in its India business, driven by a high demand for weight-loss drugs and the company's executives from its Milford branch recently represented on Wall Street. Despite ongoing industry challenges related to the strength of the dollar, Waters continues to demonstrate a robust growth, beating sales estimates in its Q1 2025. However, lowered price targets have also been voiced amid industry concerns.
The company's innovations in analytical instruments were a standout at the Jefferies Healthcare Conference 2025. Waters also anticipates strong sales growth in Q2 2025, supporting the belief that the company may be one of the most promising stocks in the scientific instruments market at present.
Waters Corp continues to outperform the healthcare sector despite some concerns about its stock having run too fast, too soon. Its Q1 2025 results revealed a GAAP EPS slightly missing at $2.03, though revenue surpassed estimates at $662m. Amid these strong performances, Waters Corp has also opened a state-of-the-art precision manufacturing facility in Longbridge, UK, further expanding its offering.
Waters Corp WAT News Analytics from Fri, 07 Oct 2022 07:00:00 GMT to Fri, 16 May 2025 15:15:37 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor -6
